David Esposito Joins Shield Diagnostics' Board of Directors
CEO Insights Team
Fred Turner, Chairman & CEO, Shield Diagnostics states, “I am pleased to welcome David to our board of directors. His guidance, expertise and deep commitment to patient care will help strengthen Shield as we advance our mission of preventing antibiotic resistance with diagnostics”.
At present, David is the President & CEO of Ann Arbor-based ONL Therapeutics. Previously, he served as the CEO of Armune BioScience, where he led the development and commercialization of blood based diagnostics to develop more personalized treatment for cancer.
Prior to this, David served as the President of Phadia US Inc. where he played a vital role in selling the business to Thermo Fisher Scientific in 2011.
David is a combat veteran. He has led an infantry platoon with the 101st Airborne Division through several combat operations. David was honored with a Bronze star for his combat action in Iraq in the year 1991. He has obtained his B.S. degree in Civil Engineering from the United States Military Academy at West Point and his MBA from Syracuse University.
Speaking on his appointment, David says, “I am honored to join the Shield Board of Directors, Shield’s technology of rapid molecular testing for antibiotic susceptibility provides an answer to the crisis of antibiotic resistance. It is one that will change the infectious disease space, and I am excited to help this innovative and talented team in this great mission.”
David is a combat veteran. He has led an infantry platoon with the 101st Airborne Division through several combat operations. David was honored with a Bronze star for his combat action in Iraq in the year 1991. He has obtained his B.S. degree in Civil Engineering from the United States Military Academy at West Point and his MBA from Syracuse University.
I am pleased to welcome David to our board of directors. His guidance, expertise and deep commitment to patient care will help strengthen Shield as we advance our mission of preventing antibiotic resistance with diagnostics
Speaking on his appointment, David says, “I am honored to join the Shield Board of Directors, Shield’s technology of rapid molecular testing for antibiotic susceptibility provides an answer to the crisis of antibiotic resistance. It is one that will change the infectious disease space, and I am excited to help this innovative and talented team in this great mission.”